Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Patients diagnosed as gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, or advanced renal cell carcinoma (aRCC) will be included in the study, or patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma.

Exclusion Criteria:

• Any patient who does not agree that Pfizer and companies working with Pfizer use his/her information will be excluded.

• Patients with hypersensitivity to sunitinib malate or to any other component of Sutent